Prospective clinical evaluation of lower cut‐offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients
Authors:
Open Access
- 16 August 2004
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 126 (6) , 852-860
Abstract
Summary: The recent advent of an improved commercial serum enzyme‐linked immunosorbent assay (ELISA) for the detection of circulating galactomannan (GM), a major constituent of Aspergillus cell walls, has contributed to the diagnosis of invasive aspergillosis (IA) in many haematology and transplant centres. However, the optimal threshold for positivity remains a matter of debate. We prospectively evaluated the impact of lowering the cut‐off in 124 neutropenic episodes with a high pretest probability for IA. Two new cut‐off points, lower than previously accepted, are proposed: (a) a ‘static’ cut‐off at 0·8 and (b) a ‘dynamic’ cut‐off at 0·5. A single assay with an optical density (OD) index ≥0·8 warrants the initiation of anti‐Aspergillus therapy. A further lowering of the ‘static’ threshold seems not clinically feasible given the drop in positive predictive value (PPV). However, the demonstration of at least two sequential sera with an OD ≥0·5 (‘dynamic’ threshold) increased the specificity and the PPV to 98·6% and the efficiency to 98%. Applying both cut‐offs to a subgroup of 21 ‘possible’ fungal infections further identified and upgraded six cases of IA. However, the clinical benefit of lower cut‐offs (particularly for earlier diagnosis) depends upon the kinetics of antigenaemia and the intensity of serum sampling.Keywords
This publication has 36 references indexed in Scilit:
- Treatment with Piperacillin‐Tazobactam and False‐PositiveAspergillusGalactomannan Antigen Test Results for Patients with Hematological MalignanciesClinical Infectious Diseases, 2004
- False‐Positive Galactomannan PlateliaAspergillusTest Results for Patients Receiving Piperacillin‐TazobactamClinical Infectious Diseases, 2004
- High Rate of Invasive Fungal Infections Following Nonmyeloablative Allogeneic TransplantationClinical Infectious Diseases, 2003
- Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factorsBlood, 2002
- Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2002
- Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patientsBritish Journal of Haematology, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002
- Aspergillosis Case-Fatality Rate: Systematic Review of the LiteratureClinical Infectious Diseases, 2001
- Early diagnosis of invasive aspergillosisThe Lancet, 2000
- Survival and Prognostic Factors of Invasive Aspergillosis After Allogeneic Bone Marrow TransplantationClinical Infectious Diseases, 1999